Table 19Studies reporting subgroup results (modifiers of effectiveness) in the IC population

StudyType of Study
N Analyzeda
Comparison
Quality
SubgroupResults Reported by Authors
Dawson, 199886RCT
N: 81
Cilostazol vs. placebo
Good
On treatment analysis (limited to those completing 12 wk of therapy)Percent change in walking distances from baseline (geometric mean)
Cilostazol (N=44): 31%
Placebo (N=22): -4.6%
Feinglass, 200091Observational
N: 526
Endovascular revascularization vs. medical therapy
Fair
Success of revascularization technique only on the revascularization groupQOL
Bypass grafting ABI change >0.1 (mean [SD]) (N=37)
  1. SF-36 physical functioning score 28 (23)
  2. WIQ walking distance score 0.43 (0.27)
  3. SF36 bodily pain score 25 (24)
  4. ABI 0.36 (0.15)
Bypass grafting ABI change <0.1 (mean [SD]) (N=23)
  1. SF36 physical functioning score -0.8 (18)
  2. WIQ walking distance score 0.01 (0.23)
  3. SF36 bodily pain score 5 (24)
  4. ABI -0.01 (0.12)
Angioplasty ABI change >0.1 (mean [SD]) (N=22)
  1. SF-36 physical functioning score 20 (23)
  2. WIQ walking distance score 0.35 (0.28)
  3. SF36 bodily pain score 12 (24)
  4. ABI 0.23 (0.11)
Angioplasty ABI change <0.1 (mean [SD]) (N=22)
  1. SF-36 physical functioning score 7 (17)
  2. WIQ walking distance score 0.20 (0.26)
  3. SF-36 bodily pain score 13 (18)
  4. ABI -0.01 (0.01)
Gelin, 200170RCT
N: 264
Supervised exercise vs. invasive therapy (surgical or endovascular) vs. control
Fair
Suprainguinal vs. infrainguinal reconstructions1-yr patency
Suprainguinal 89% (24 of 27)
Infrainguinal 76% (26 of 34)
p-value not provided by author; our calculated p-value=0.21
Mori, 200276Observational
N: 427
Surgical revascularization vs. usual care
Poor
Suprainguinal patency
  1. Aortofemoral bypass
  2. Axillofemoral bypass
  3. Femorofemoral bypass
Suprainguinal patency
  1. 95.1%
  2. 95.5%
  3. 83.3%
Infrainguinal patency
  1. Above knee femoropopliteal bypass
  2. Below knee femoropopliteal bypass
Infrainguinal patency
  1. 67.6%
  2. 45.2%
Above knee bypass
  1. Synthetic graft
  2. Auto vein graft
Above knee bypass
  1. 64.2%
  2. 85.7%
Below knee bypass
  1. Synthetic graft
  2. Auto vein graft
Below knee bypass
  1. 38.9%
  2. 57.1%
5 yr
Perkins, 199684RCT
N: 56
Endovascular revascularization vs. supervised exercise
Fair
Iliac stenosis vs. superficial femoral stenosis in exercise vs. PTAMedian MWD at 15 mo (SE)
SFA stenosis:
PTA (N=15) 161.43 (66), exercise (N=13) 723.8 (124.7)
Iliac stenosis:
PTA (N=15) 171.3 (125.8), exercise (N=13) 374.3 (96)
Soga, 200951RCT
N: 78
Cilostazol vs. placebo
Good
Occlusive vs. nonocclusive diseaseRepeat revascularization
Occlusive disease:
 Cilostazol 50%
 Placebo 36%
Nonocclusive disease:
 Cilostazol 3.4%
 Placebo 39%
a

Number of patients in the study arms of interest.

Abbreviations: ABI=ankle-brachial-index; ACD=absolute claudication distance; ICD=initial claudication distance; MWD=maximal walking distance; PTA=percutaneous transluminal angioplasty; QOL=quality of life; RCT=randomized controlled trial; SD=standard deviation; SE=standard error; SFA=superficial femoral artery; WIQ=Walking Impairment Questionnaire.

From: Results

Cover of Treatment Strategies for Patients With Peripheral Artery Disease
Treatment Strategies for Patients With Peripheral Artery Disease [Internet].
Comparative Effectiveness Reviews, No. 118.
Jones WS, Schmit KM, Vemulapalli S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.